Unilever is still interested in the GSK-Pfizer joint, despite its £50 billion deal being rejected

Posted by : admin / On : 18 Jan 2022

After a proposal of £50 billion ($68 billion) was rejected, consumer goods giant Unilever NSE -0.57% indicated a persistent interest in a consumer health care unit jointly held by pharmaceutical companies GlaxoSmithKline and Pfizer NSE -0.66 percent. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement released in the aftermath of the buyout news over the weekend. "We are dedicated to accelerating the companys growth and shifting the portfolio into higher-growth areas," Unilever added.

After a proposal of £50 billion ($68 billion) was rejected, consumer goods giant Unilever NSE -0.57% indicated a persistent interest in a consumer health care unit jointly held by pharmaceutical companies GlaxoSmithKline and Pfizer NSE -0.66 percent. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement released in the aftermath of the buyout news over the weekend. "We are dedicated to accelerating the companys growth and shifting the portfolio into higher-growth areas," Unilever added.